Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;52(6):2239-41.
doi: 10.1128/AAC.00009-08. Epub 2008 Mar 31.

In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin

Mahtab Moayeri  1 , Tanisha M Robinson, Stephen H Leppla, Vladimir A Karginov
Affiliations

In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin

Mahtab Moayeri et al. Antimicrob Agents Chemother. 2008 Jun.

Abstract

We evaluated the in vivo efficacy of three beta-cyclodextrin derivatives that block the anthrax protective antigen pore. These compounds were at least 15-fold more potent than previously described beta-cyclodextrins in protecting against anthrax lethal toxin in a rat model. One of the drugs was shown to protect mice from bacterial infection.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Protection of mice from B. anthracis infection. Mice challenged with B. anthracis Sterne spores were treated on days 1 to 10 with compound 14b (2.5 mg/kg/day i.v.) alone, with ciprofloxacin (CIPRO) alone (50 mg/kg/day i.p.), or with both compound 14b and ciprofloxacin (by the same schedule used for each compound alone) and survival was monitored. The graph presents the results of a single representative experiment selected to show the lowest survival rates. The combination of ciprofloxacin with compound 14b was significantly (P = 0.02) more effective at protecting the mice than antibiotic treatment alone. In a second set of experiments, 90% of animals treated with compound 14b and ciprofloxacin survived.
See this image and copyright information in PMC

References

    1. Albrecht, M. T., H. Li, E. D. Williamson, C. S. Lebutt, H. C. Flick-Smith, C. P. Quinn, H. Westra, D. Galloway, A. Mateczun, S. Goldman, H. Groen, and L. W. Baillie. 2007. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 75:5425-5433. - PMC - PubMed
    1. Chen, Z., M. Moayeri, Y. H. Zhou, S. Leppla, S. Emerson, A. Sebrell, F. Yu, J. Svitel, P. Schuck, C. M. St. Claire, and R. Purcell. 2006. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 193:625-633. - PMC - PubMed
    1. Ezzell, J. W., B. E. Ivins, and S. H. Leppla. 1984. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect. Immun. 45:761-767. - PMC - PubMed
    1. Firoved, A. M., G. F. Miller, M. Moayeri, R. Kakkar, Y. Shen, J. F. Wiggins, E. M. McNally, W. J. Tang, and S. H. Leppla. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167:1309-1320. - PMC - PubMed
    1. Ivins, B., P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13:1779-1784. - PubMed

Publication types

LinkOut - more resources